Resuscitative endovascular balloon occlusion of the aorta in Canada: a context-specific position paper from the Canadian Collaborative for Urgent Care Surgery (CANUCS)
We created statements and recommendations for use of REBOA in Canadian centres in stages. First, 1 investigator (N.L.B.) searched MEDLINE and PubMed for articles mentioning use of REBOA in their title or abstract, including relevant REBOA primary studies, systematic reviews, and clinical practice statements or guidelines. Searches used the keywords “resuscitative balloon occlusion of the aorta” or “REBOA” as relevant Medical Subject Heading indexing terms are not yet available. We also reviewed bibliographies of studies and asked CANUCS members for other studies, unpublished documents or data (e.g., unpublished provincial or hospital-based data, such as the number of REBOA deployments since implementing a REBOA program), or society or college statements relevant to the creation of recommendations specific to the Canadian context. With the assistance of a CANUCS member who had fellowship training in vascular and endovascular surgery (D.J.R.), we also conducted secondary literature searches from related surgical or interventional disciplines if we could not identify any studies that included our target patient population of trauma patients (e.g., safe vascular access techniques in vascular surgery and interventional radiology).

We then shared identified studies with members of the CANUCS and held several iterative virtual meetings (Zoom Video Communications) and group email threads to discuss potential issues relevant to the implementation of REBOA in Canadian trauma centres. Numerous co-authors have direct experience with REBOA insertion, use and education in Canada, the US and Africa. During these meetings, members discussed the existing literature and clinical practice statements or guidelines identified by the search.

Thereafter, using a modified Delphi process, we created a list of context-specific statements (which provided rationale for our recommendations and, in some cases, literature-based benchmarks for REBOA use) and recommendations for implementation of REBOA in Canada. During this process, we considered whether recommendations created to guide use of REBOA in other countries applied to the Canadian context. The goal of these meetings was to achieve consensus regarding recommendations. If consensus could not be reached, we did not provide a recommendation. We presented statements and recommendations, followed by a description of the literature supporting the statement and the rationale for creation of the statement (Box 1). We used this process instead of that recommended in the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) guidelines because insufficient literature yet exists to conduct a formal GRADE evaluation on implementation of a REBOA program. At the time of literature synthesis, we identified 1 report describing a single centre’s first year of their REBOA program, with a focus on system improvement, and 1 guideline for a multidisciplinary approach to institutional REBOA programs based on a panel of 6 trauma and vascular surgeons from Level 1 trauma centres in the US. We did not identify any published randomized controlled trials on REBOA in human participants; we look forward to the results of UK-REBOA to inform future recommendations. Most primary publications on REBOA use in humans consist of retrospective reviews, prospective observational studies and case series or case reports. This is consistent with Level III or IV evidence, as per the Oxford Centre for Evidence-Based Medicine; expert opinion guidelines are Level V evidence.

A recent systematic review on REBOA for major exsanguination included 89 studies; 57 of 61 case series and cohort studies were at high risk of bias, as per the Cochrane Collaboration tool (not applied to 28 case reports). Current primary studies would have a moderate, serious or critical risk of bias as per the Risk Of Bias In Non-Randomized Studies of Interventions (ROBINS-I) tool, and were not designed to evaluate...
processes of care within REBOA programs. We have interpreted the available information with these limitations in mind, driven by an understanding of both REBOA use and the Canadian health care system, to prioritize patient safety during implementation of REBOA programs. As the literature evolves, and the Canadian experience with REBOA grows, we expect to modify our recommendations accordingly.

**CLINICAL PRACTICE STATEMENTS**

**Statement 1:** The busiest trauma centres in Canada may expect fewer than 15 trauma patients who could potentially benefit from REBOA per year

**Rationale:** Although the Trauma Quality Improvement Program database recorded a median of 6 (interquartile range 4–7) REBOA cases per year in 2019,1 the busiest trauma centres in the US report up to 70 REBOA deployments annually.9 The frequency of REBOA use in Canada appears to be more consistent with reports from Japan (6 cases per year)18,19 and the United Kingdom (3–8 cases per year).5 A recent gap analysis from 2 trauma centres in Alberta identified 30 patients who could have potentially benefitted from REBOA over a 2-year period.14 This is consistent with an estimate of up to 15 cases of REBOA use annually reported by the Vancouver General Hospital (N. Garraway, personal communication, 2020) and up to 6 cases by the Nova Scotia Trauma Program, based on an internal needs assessment (unpublished data). In the 2 years after the implementation of REBOA programs at Montreal General Hospital, Vancouver General Hospital and St. Michael’s Hospital in Toronto in 2018, there have been 27, 5 and 4 REBOA deployments, respectively (unpublished data; N. Garraway, personal communications, 2021).

**Statement 2:** In Canada, trauma team members and leaders have variable training and skill sets for accessing the common femoral artery percutaneously or via open surgical cutdown

**Rationale:** Open surgical cutdowns were required in up to 50% of REBOA placements in the initial AORTA (Aortic Occlusion for Resuscitation in Trauma and Acute Care Surgery) registry.1 More recent data indicated that 17%–24% of REBOA placements required surgical cutdown for access to the common femoral artery (CFA).4,21 A 6-year review of the International ABOTrauma Registry reported that the CFA was accessed percutaneously in 72% of cases, either by using anatomic landmarks (51%) or ultrasonography (21%), and was accessed by open surgical cutdown in 24% of cases.21 The impact of the newly developed COBRA system (using a 4-French sheath and balloon) on procedure success and complications in trauma patients has not yet been explored in clinical settings.22 Patients in cardiac arrest are more likely to require surgical cutdown to facilitate REBOA placement.1,3,21 Having immediate skills available to appropriately access the CFA is predictive of both speed of REBOA deployment and lower rates of procedural complications.5,23

Several trauma care models exist nationally, but many sites have trauma team leaders as a shared duty between surgeon and nonsurgeon trauma physicians. In addition, trauma team leaders are not always on site. As a result of this mixed provider model, experience with CFA access is more variable in Canada. Thus, advanced surgical techniques, such as open surgical cutdown for CFA access, may not be immediately available in many Canadian trauma centres. In addition, general surgery residency programs in Canada provide inconsistent training in vascular and endovascular surgery. Although general surgery trainees are often present early in trauma resuscitation, many have minimal surgical experience operating on the femoral artery or gaining CFA access for endovascular procedures. Conversely, with the Royal College of Canada’s direct-entry vascular surgery program, current vascular surgery trainees have less experience managing multisystem trauma patients than previous general surgery fellows.

**Statement 3:** In Canada, nearly one-quarter of the population lives more than a 1-hour drive from a level 1 or 2 trauma centre

**Rationale:** Geographic data reveal that 22.5% of people in Canada live more than a 1-hour drive from a level 1 or 2 trauma centre.24 The presenting physiology of trauma patients living in rural Canada may therefore be different than their urban counterparts. Even if patients ultimately reach an urban centre, transferred trauma patients have significantly higher risk-adjusted mortality than those who are admitted directly.25 Thus, REBOA outcomes in trauma patients in Canada may differ from results reported elsewhere. These realities pose challenges to identifying appropriate patients and logically staffing a REBOA program at a Canadian trauma hospital; these realities must be considered before an institution initiates REBOA.

**CLINICAL PRACTICE RECOMMENDATIONS**

**REBOA Placement**

**Recommendation 1:** Individual institutions should be responsible for credentialling REBOA providers and developing protocols to optimize patient care

**Rationale:** We recommend that REBOA privileges be limited to providers with appropriate training and skills
to access the CFA percutaneously or via open surgical cutdown.\textsuperscript{6,10} Certification from a REBOA course should be part of the credentialing process. Although a course does not confer system success,\textsuperscript{17} it does provide a baseline from which to develop an institutional REBOA program.\textsuperscript{26} Representatives from vascular and endovascular surgery, trauma and acute care surgery, emergency and critical care medicine, anesthesiology, interventional radiology, nursing and hospital administration must be involved in developing institutional REBOA protocols. Tracking and management of REBOA-related complications must be considered in these protocols.\textsuperscript{9,10,17,27}

**Recommendation 2: Access for REBOA placement should be limited to the common femoral artery, directly over the femoral head**

**Rationale:** Arterial access for REBOA should be limited to the CFA to allow the artery to be compressed against the underlying femoral head and to limit complications, including access site hematomas, pseudoaneurysm formation, retroperitoneal hemorrhage and limb loss.\textsuperscript{2,13,23} We recommend using ultrasonography to guide access to the CFA whenever possible.\textsuperscript{1} As percutaneous access will not always be possible, all items required for percutaneous access and open surgical CFA cutdown should be immediately available in designated locations for REBOA cannulation.\textsuperscript{10} Further, a complete REBOA placement and securement kit should be assembled locally and simulated before use with patients.\textsuperscript{10,27}

**Recommendation 3: The position of the REBOA balloon should be confirmed before inflation**

**Rationale:** Current evidence supports plain radiography or fluoroscopy to confirm the position of the REBOA balloon in aortic zone I (located between the left subclavian and celiac artery) or zone III (located between the lowest renal artery and aortic bifurcation) before deployment.\textsuperscript{1,3,9} Ultrasoundography can identify wire position within the aorta, but has not yet been validated to confirm balloon position.\textsuperscript{28}

Lack of radiologic confirmation of the balloon position should be limited to exceptional situations, such as patients receiving cardiopulmonary resuscitation; radiologic confirmation should then be obtained as soon as possible. Thus, radiologic technologists and imaging must be immediately available where REBOA will be deployed. We recommend using patient stretchers that permit radiography without turning patients with REBOA in situ.

**Recommendation 4: REBOA deployment should follow the manufacturers’ instructions for use**

**Rationale:** Balloon inflation should follow manufacturers’ instructions for use. An arterial line set-up that connects to the REBOA catheter must be available to monitor blood pressure response to aortic occlusion. Overinflation may result in balloon or arterial rupture.\textsuperscript{1,9} Although some centres and providers have advocated partial balloon inflation,\textsuperscript{27} partial REBOA has not yet been appropriately studied for use in civilian settings. A partially inflated balloon may migrate, causing intimal injury or iliac artery positioning.\textsuperscript{3,9} Based on currently available evidence, and the expected low volume of REBOA cases at Canadian institutions, we do not advocate for partial inflation as part of institutional protocols.

**Recommendation 5: Institutions must have physician resources to monitor the patient during balloon deployment**

**Rationale:** Increases in blood pressure after REBOA deployment can cause balloon migration or create flow around the balloon, precluding adequate occlusion.\textsuperscript{9} Institutions implementing REBOA must have resources to completely dedicate an appropriately trained physician to monitor balloon position and appropriate occlusion, and to manage the balloon until definitive hemorrhage control is achieved.

**Patient management after REBOA inflation**

**Recommendation 6: Zone 1 aortic occlusion should be less than 30 minutes and should not be performed without a certified trauma, acute care or vascular surgeon present, with institutional capacity to meet these constraints**

**Rationale:** A safe duration of zone 1 REBOA occlusion in trauma patients has not been defined by randomized controlled trials. Data from animal studies suggest that a balloon inflation time of up to 30 minutes is well tolerated, but 60 minutes results in an overwhelming physiologic insult that negates benefit.\textsuperscript{10} A case series from Japan also reported a 50% mortality rate with a median balloon occlusion time of 65 minutes.\textsuperscript{18} Thus, the goal occlusion time in zone 1 is less than 30 minutes.\textsuperscript{3,11,13} To achieve this goal, zone 1 should not be occluded unless the hemorrhage control procedure can begin within 15 minutes of occlusion.\textsuperscript{9} Thus, zone 1 should not be occluded without a trauma or acute care surgeon present.\textsuperscript{3} In addition, zone 1 should not be occluded in institutions that cannot accommodate immediate operating room availability.

**Recommendation 7: Zone 3 occlusion should be less than 60 minutes**

**Rationale:** Definitive data on the safe duration of zone 3 aortic occlusion in trauma patients are not yet available. However, experts have suggested that zone 3 should only be occluded if the hemorrhage control procedure can begin within 30 minutes so that
hemorrhage control can be achieved in 60 minutes. Survival after longer zone 3 occlusion times has been reported, but is associated with serious complications.

**Recommendation 8: Institutions transferring patients with zone 3 aortic occlusion to an interventional radiology suite must have in-suite capacity for resuscitative interventions**

**Rationale:** To ensure additional procedures can be performed if necessary, capacity includes supplies or processes (e.g., thoracostomy and central line kits, massive transfusion capability) and personnel (e.g., surgeons, anesthesiologists, respiratory therapists). Further, institutions implementing REBOA without a hybrid operating room suite should have a protocol for transfer from the operating room to interventional radiology and vice versa.

**Recommendation 9: REBOA should only be deployed in sites with the capacity for definitive hemorrhage control**

**Rationale:** Successful use of REBOA has been previously described in austere, prehospital, rural and transfer environments. However, Canadian paramedic and air ambulance services have variable provider models, resources and transfer times. In Canada, it is not feasible at this time to transfer a patient with in situ REBOA such that appropriately trained health care professionals can manage the REBOA and achieve the recommended timeline to the operating room and interventional radiology at the receiving site.

**Recommendation 10: Institutional protocols for device removal and patient monitoring after REBOA are necessary and should be developed in conjunction with colleagues from vascular and endovascular surgery and from critical care medicine**

**Rationale:** After hemorrhage control, the REBOA balloon must be deflated, and the catheter and sheath must be removed as soon as possible. An ankle-brachial index (ABI) should be recorded after balloon deflation and before leaving the operating room–interventional radiology suite. An ABI of 1.0–1.2 is considered normal in patients with compressible, non-calcified arteries. To continue invasive blood pressure monitoring, radial arterial access is recommended before removal of REBOA.

Institutional protocols for device removal and patient monitoring after REBOA are necessary. These protocols should be developed with vascular and endovascular surgery, as well as critical care medicine. If vascular and endovascular surgeons are not present for REBOA device removal, indications for consultation must be clearly defined. Vascular examinations of the lower extremity and access site must be performed for at least 24 hours. Hourly neurovascular assessments should occur, as per local protocol. There should be a low threshold for computed angiographic assessment after an abnormal physical examination, including an ABI less than 0.9. In addition, assessment for pseudoaneurysm formation within 48 hours after percutaneous sheath removal is recommended.

**Quality assurance and quality improvement**

**Recommendation 11: Institutions implementing REBOA should have multidisciplinary education, simulation, review and maintenance of skills programs**

**Rationale:** Stakeholder education (including vascular and endovascular surgery, emergency medicine, nursing, interventional radiology, critical care, anesthesiology, trauma and acute care surgery) is necessary for institutions to prepare for introduction of a REBOA program. Multidisciplinary (including nurses, physicians, resident physicians, respiratory therapists, anesthesia assistants, radiologists), in situ simulation training is recommended before in vivo REBOA deployment.

Further, all REBOA deployments should be reviewed by a multispecialist panel to assess for appropriate indications. Ongoing competency and maintenance of skills is required and should follow institutional requirements. This would ideally include wet laboratories, task trainers, and multidisciplinary simulation. REBOA procedures should be coded using the classification from the International Classification of Diseases, 10th edition (ICD-10), namely REBOA ICD-10 04L03DZ. Canadian sites participating in REBOA deployment should contribute to a quality assurance or improvement registry (e.g., the AORTA registry).

**Recommendation 12: Institutions implementing REBOA should have a surgical REBOA coordinator**

**Rationale:** A REBOA site coordinator guides the process of deployment, dwell time and removal. The coordinator should be the primary contact with consulting services and leadership of the operating room, interventional radiology, emergency department and intensive care unit. Although different specialties have been successfully trained to insert and deploy REBOA in the Canadian context, the hospital REBOA coordinator should be a trauma or vascular and endovascular surgeon.

**Conclusion**

Resuscitative endovascular balloon occlusion of the aorta is a well-described intervention for noncompressible
torso hemorrhage. However, REBOA has known complications and equipoise persists regarding its use. In Canada, case volumes, composition of trauma teams, experience with vascular access and geography create unique challenges for implementing and supporting REBOA programs. This context-specific position paper provides guidance for Canadian trauma centres regarding REBOA credentialling, multidisciplinary education, logistics and quality assurance to maximize patient benefits and minimize risks.

Affiliations: From the Department of Surgery, University of Alberta, Edmonton, Alta. (Bradley, Wilder, Kim); the Department of Surgery, Western University, London, Ont. (Leeper, Parry, Vogt); the Department of Surgery, University of Ottawa, Ottawa, Ont. (Roberts, Lampron); the Department of Surgery, University of Calgary, Calgary, Alta. (Ball, Kirkpatrick); the Department of Surgery, University of Toronto, Toronto, Ont. (Beckett, Neto Rezende, Ahmed, Gomez); the Department of Surgery, McMaster University, Hamilton, Ont. (Engels, Nenshi, Rice); the Department of Surgery, University of British Columbia, Vancouver, BC (Joos, Hamed); the Department of Surgery and of Critical Care Medicine, McGill University, Montréal, Qué. (Khwaja); the Department of Surgery, Dalhousie University, Halifax, NS (Minor); the Department of Surgery, University of Manitoba, Winnipeg, Man. (Gillilan); the Department of Surgery, Medical College of Wisconsin, Milwaukee, Wis. (Murphy).

Competing interests: Andrew Kirkpatrick has consulted for Zoll, Innovative Trauma Care, CSL Behring and SAM Medical Corporations, and is the principal investigator of a prospective randomized controlled trial that is partially supported by the Acelity Corporation (https://clinicaltrials.gov/ct2/show/NCT03163095). No other competing interests were declared.

Contributors: All of the authors contributed to the conception and design of the work. Nori Bradley, W. Robert Leeper and Derek Roberts drafted the manuscript. All of the authors revised it critically for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC-BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

Disclaimer: Chad Ball is co-editor-in-chief of the Canadian Journal of Surgery. Andrew Beckett, Paul Engels, Neil Parry and Kelly Vogt are on the editorial board of the Canadian Journal of Surgery. They were not involved in the editorial decision-making process for this article.

References

1. DuBose JJ, Scalea TM, Brenner ML, et al. The AAST prospective Aortic Occlusion for Resuscitation in Trauma and Acute Care Surgery (AORTA) registry: Data on contemporary utilization and outcomes of aortic occlusion and resuscitative balloon occlusion of the aorta (REBOA). J Trauma Acute Care Surg 2016;81:409-19.
2. Bekdache O, Paradis T, Shen YBH, et al. Resuscitative endovascular balloon occlusion of the aorta (REBOA): indications, advantages and challenges of implementation in traumatic non-compressible torso hemorrhage. Trauma Surg Acute Care Surg 2019;4:e000262.
3. Bulger EM, Perina DG, Qasim Z, et al. Clinical use of resuscitation endovascular balloon occlusion of the aorta in civilian trauma systems in the USA, 2019: a joint statement from the American College of Surgeons Committee on Trauma, the American Emergency Physicians, the National Association of Emergency Medical Services Physicians and the National Association for Emergency Medical Technicians. Trauma Surg Acute Care Open 2019;4:e00376.
4. Manzano-Nunez R, McGreevy D, Orlas CP, et al. Outcomes and management approaches of resuscitative endovascular balloon occlusion of the aorta based on the income of countries. World J Emerg Surg 2020;15:57.
5. Osbourn LA, Brenner M, Prater SJ, et al. Resuscitative endovascular balloon occlusion of the aorta: current evidence. Open Access Emerg Med 2019;11:29-38.
6. Paradis T, Bekdache O, Bracco D, et al. Deployment of second-generation resuscitative balloon occlusion of the aorta for unresponsive hypotension in a polytrauma patient. Can J Surg 2019;62:142-4.
7. Zeismann MT, Rezende-Neto J, McKendy K, et al. In the zone: lessons from the first emergency department application of resuscitative endovascular balloon occlusion of the aorta. Can J Emerg Med 2019;21:420-34.
8. Joseph B, Zeeshan M, Sakran JV, et al. Nationwide analysis of resuscitative endovascular balloon occlusion of the aorta in civilian trauma. JAMA Surg 2019;154:500-8.
9. Brenner M, Bulger EM, Perina DG, et al. Joint statement from the American College of Surgeons Committee on Trauma (ACS COT) and the American College of Emergency Physicians (ACEP) regarding the clinical use of resuscitative endovascular balloon occlusion of the aorta (REBOA). Trauma Acute Care Open 2018;3:1-3.
10. Zakaluszy SA, Beldowicz BG, Salcedo ES, et al. Guidelines for a system-wide multidisciplinary approach to institutional resuscitative endovascular balloon occlusion of the aorta implementation. J Trauma Acute Care Surg 2019;86:337-43.
11. Guideline JTSCP: Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) for Hemorrhagic Shock (CPG ID:38). Revised publication Mar 2020.
12. Parra MW, Rezende-Neto JB, Brenner ML, et al. Resuscitative endovascular balloon occlusion of the aorta consensus: the pan-American experience. Panam J Trauma Crit Care Emerg Surg 2018;7:171-82.
13. Borgner van der Burg LS, Kessel B, DuBose JJ, et al. Consensus on resuscitative endovascular balloon occlusion of the aorta: a first consensus paper using a Delphi method. Injury 2019;50:1186-91.
14. Eksteen A, O’Dochartaigh D, Odenbach J, et al. A gap analysis of the potential use of resuscitative endovascular balloon occlusion of the aorta (REBOA) in trauma at two major Canadian trauma centers. CJFM 2021;23:36-44.
15. Smith SA, McAlister AC. A novel REBOA system: prototype and proof of concept. Can J Surg 2018;61(Suppl 1):S188-94.
16. Gwaltney G, Osman AD, Akil EA, et al. GRADE guidelines: 1. Introduction — GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383-94.
17. Theodorou CM, Salcedo ES, DuBose JJ, et al. Hate to burst your balloon: successful REBOA use takes more than a course. J Endovasc Resusc Trauma Manag 2020;4:21-9.
18. Sato R, Kuriyama A, Takaesu R, et al. Resuscitative endovascular balloon occlusion of the aorta performed by emergency physicians for traumatic hemorrhagic shock: a case series from Japanese emergency rooms. Crit Care 2018;22:103.
19. Matsumura Y, Matsumoto J, Kondo H, et al. Early arterial access for traumatic hemorrhagic shock: a case series from Japanese emergency rooms. Crit Care 2019;21:420-34.
21. Hilbert-Carius P, McGreevy D, Abu-Zidan FM. Successful REBOA performance: does medical specialty matter? International data from the ABOTrauma Registry. *World J Emerg Surg* 2020;15:62.

22. Power A, Parekh A, Scallon O, et al. Size matter: first-in-human study of a novel 4 French REBOA device. *Trauma Surg Acute Care Open* 2021;6:e000617.

23. Romagnoli A, Teeter W, Pasley J, et al. Time to aortic occlusion: It's all about access. *J Trauma Acute Care Surg* 2017;83:1161-4.

24. Hameed SM, Schuurman N, Razek T, et al. Access to trauma systems in Canada. *J Trauma* 2010;69:1350-61.

25. Gleich SJ, Bennet TD, Bratton SL, et al. Pediatric trauma transport performance measures in a mountain state: adherence and outcomes. *J Trauma* 2011;71:1016-22.

26. Brenner M, Hoehn M, Pasley J, et al. Basic endovascular skills for trauma course: bridging the gap between endovascular techniques and the acute care surgeon. *J Trauma Acute Care Surg* 2014;77:286-91.

27. Qasim Z, Bradley K, Panichelli H, et al. Successful interprofessional approach to development of a resuscitative endovascular occlusion of the aorta program at a community trauma center. *J Emerg Med* 2018;54:419-26.

28. Ogura T, Lefor AK, Nakamura M, et al. Ultrasound-guided resuscitative endovascular balloon occlusion of the aorta in the resuscitation area. *J Emerg Med* 2017;52:715-22.

29. DuBose JJ. How I do it: Partial resuscitative endovascular balloon occlusion of the aorta (P-REBOA). *J Trauma Acute Care Surg* 2017;83:197-9.

30. Reva VA, Matsumura Y, Hörer T, et al. Resuscitative endovascular balloon occlusion of the aorta: what is the optimum occlusion time in an ovine model of hemorrhagic shock? *Eur J Trauma Emerg Surg* 2018;44:511-8.

31. Kauvar DS, Dubick MA, Martin MJ. Large animal models of proximal aortic balloon occlusion in traumatic hemorrhage: review and identification of knowledge gaps relevant to expanded use. *J Surg Res* 2019;236:247-58.

32. Matsumoto J, Lohman BD, Morimoto K, et al. Damage control interventional radiology (DCIR) in prompt and rapid endovascular strategies in trauma occasions (PRESTO): a new paradigm. *Diagn Interv Imaging* 2015;96:687-91.

33. Manley JD, Mitchell BJ, DuBose JJ, et al. A modern case series of resuscitative endovascular balloon occlusion of the aorta (REBOA) in an out-of-hospital, combat casualty care setting. *J Spec Oper Med* 2017;17:1-8.

34. Sadek S, Lockey DJ, Lendrum RA, et al. Resuscitative endovascular balloon occlusion of the aorta (REBOA) in the pre-hospital setting: an additional resuscitation option for uncontrolled catastrophic haemorrhage. *Resuscitation* 2016;107:135-8.

35. Lamhaut L, Qasim Z, Hutin A, et al. First description of successful use of zone 1 resuscitative endovascular balloon occlusion of the aorta in the prehospital setting. *Resuscitation* 2018;133:e1-2.

36. Vernamonti JP, Holcomb J, Mick NW, et al. A ‘step up’ approach to the application of REBOA technology in a rural trauma system. *Trauma Surg Acute Care Open* 2019;4:e000335.

37. Beldowicz BC, Salcedo ES, Galante JM. Resuscitative endovascular balloon occlusion of the aorta in interhospital transfers: two case reports. *J Endovasc Resusc Trauma Manag* 2018;2:44-8.